|
Volumn 3, Issue 12, 2015, Pages 930-931
|
Understanding EMPA-REG OUTCOME
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ALBUMIN;
AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE;
EMPAGLIFLOZIN;
GLITAZONE DERIVATIVE;
METFORMIN;
PLACEBO;
ROSIGLITAZONE;
SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR;
SULFONYLUREA;
ANTIDIABETIC AGENT;
BENZHYDRYL DERIVATIVE;
GLUCOSIDE;
CARDIOVASCULAR MORTALITY;
CARDIOVASCULAR RISK;
DEATH;
DIABETES MELLITUS;
DIASTOLIC DYSFUNCTION;
EXERCISE;
HEART FAILURE;
HEART VENTRICLE COMPLIANCE;
HEMATOCRIT;
HUMAN;
LETTER;
LIFESTYLE MODIFICATION;
NON INSULIN DEPENDENT DIABETES MELLITUS;
PRIORITY JOURNAL;
PROTEIN URINE LEVEL;
RISK REDUCTION;
CARDIOVASCULAR DISEASES;
DIABETES MELLITUS, TYPE 2;
FEMALE;
MALE;
BENZHYDRYL COMPOUNDS;
CARDIOVASCULAR DISEASES;
DIABETES MELLITUS, TYPE 2;
FEMALE;
GLUCOSIDES;
HUMANS;
HYPOGLYCEMIC AGENTS;
MALE;
|
EID: 84947940944
PISSN: 22138587
EISSN: 22138595
Source Type: Journal
DOI: 10.1016/S2213-8587(15)00427-1 Document Type: Letter |
Times cited : (13)
|
References (6)
|